Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $207.00

Ascendis Pharma A/S (NASDAQ:ASND) had its target price raised by Stifel Nicolaus from $200.00 to $207.00 in a report released on Friday,Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

Several other research analysts also recently issued reports on ASND. The Goldman Sachs Group lifted their price objective on Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a research report on Tuesday, September 17th. TD Cowen boosted their price target on Ascendis Pharma A/S from $157.00 to $160.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Jefferies Financial Group boosted their target price on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a “buy” rating in a research note on Tuesday, August 13th. Wedbush reaffirmed an “outperform” rating and set a $181.00 price target on shares of Ascendis Pharma A/S in a research note on Friday. Finally, Wells Fargo & Company lifted their price target on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an “overweight” rating in a report on Tuesday, September 17th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $191.77.

Ascendis Pharma A/S Stock Up 1.8 %

Shares of ASND stock opened at $126.51 on Friday. The stock has a market cap of $7.67 billion, a P/E ratio of -15.66 and a beta of 0.66. Ascendis Pharma A/S has a fifty-two week low of $90.13 and a fifty-two week high of $161.00. The business has a fifty day simple moving average of $132.30 and a 200-day simple moving average of $132.60.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The company had revenue of $38.75 million for the quarter, compared to analysts’ expectations of $94.74 million. On average, sell-side analysts anticipate that Ascendis Pharma A/S will post -7.3 earnings per share for the current year.

Hedge Funds Weigh In On Ascendis Pharma A/S

A number of hedge funds have recently made changes to their positions in the stock. Signaturefd LLC increased its holdings in shares of Ascendis Pharma A/S by 13.2% during the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after buying an additional 80 shares during the last quarter. Profund Advisors LLC grew its position in Ascendis Pharma A/S by 3.0% during the second quarter. Profund Advisors LLC now owns 2,919 shares of the biotechnology company’s stock valued at $398,000 after acquiring an additional 85 shares during the period. Rhumbline Advisers grew its position in Ascendis Pharma A/S by 10.3% during the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after acquiring an additional 143 shares during the period. Thrivent Financial for Lutherans increased its stake in Ascendis Pharma A/S by 0.3% during the third quarter. Thrivent Financial for Lutherans now owns 78,473 shares of the biotechnology company’s stock worth $11,717,000 after acquiring an additional 228 shares during the last quarter. Finally, Avior Wealth Management LLC raised its holdings in shares of Ascendis Pharma A/S by 3.0% in the 3rd quarter. Avior Wealth Management LLC now owns 8,212 shares of the biotechnology company’s stock worth $1,226,000 after purchasing an additional 240 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.